Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Environ Manage ; 368: 122056, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39142098

RESUMO

Currently, China is at a critical stage of accelerating the green transformation of its economic development model, with considerable attention being paid to achieving this transformation while maintaining moderate economic growth. This study uses 271 prefecture-level cities in China from 2006 to 2020 to examine the impact of local government economic growth target constraints on the level of green economic development and to elucidate the underlying mechanisms. The results show that economic growth targets significantly inhibit the level of urban green development, with this effect being more pronounced in the economically developed eastern regions of China. Hard constraints on economic growth targets have a greater inhibitory effect on green development than soft constraints. The greater the promotion pressure on local officials, the stronger the inhibitory effect of economic growth target constraints on green development. The test of the mediation effect model reveals that economic growth targets can inhibit green development by affecting the degree of regional marketization, leading to mismatches in the capital and labor markets. Moreover, environmental regulations can mitigate the inhibitory effect of economic growth targets on green development levels. The conclusions of this study provide useful insights for local governments to optimize economic development target constraint mechanisms and accelerate high-quality green economic development.


Assuntos
Desenvolvimento Econômico , China , Conservação dos Recursos Naturais , Cidades , Motivação
2.
J Alzheimers Dis ; 89(1): 67-77, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35848021

RESUMO

BACKGROUND: Both INPP5D and INPP5F are members of INPP5 family. INPP5F rs117896735 variant was associated with Parkinson's disease (PD) risk, and INPP5D was an Alzheimer's disease (AD) risk gene. However, it remains unclear about the roles of INPP5F rs117896735 variant in AD. OBJECTIVE: We aim to investigate the roles of rs117896735 in AD. METHODS: First, we conducted a candidate variant study to evaluate the association of rs117896735 variant with AD risk using the large-scale AD GWAS dataset. Second, we conducted a gene expression analysis of INPP5F to investigate the expression difference of INPP5F in different human tissues using two large-scale gene expression datasets. Third, we conducted an expression quantitative trait loci analysis to evaluate whether rs117896735 variant regulate the expression of INPP5F. Fourth, we explore the potentially differential expression of INPP5F in AD and control using multiple AD-control gene expression datasets in human brain tissues and whole blood. RESULTS: We found that 1) rs117896735 A allele was associated with the increased risk of AD with OR = 1.15, 95% CI 1.005-1.315, p = 0.042; 2) rs117896735 A allele could increase INPP5F expression in multiple human tissues; 3) INPP5F showed different expression in different human tissues, especially in brain tissues; 4) INPP5F showed significant expression dysregulation in AD compared with controls in human brain tissues. CONCLUSION: Conclusion: We demonstrate that PD rs117896735 variant could regulate INPP5F expression in brain tissues and increase the risk of AD. These finding may provide important information about the role of rs117896735 in AD.


Assuntos
Doença de Alzheimer , Doença de Parkinson , Alelos , Doença de Alzheimer/genética , Doença de Alzheimer/metabolismo , Encéfalo/metabolismo , Predisposição Genética para Doença/genética , Estudo de Associação Genômica Ampla , Humanos , Inositol Polifosfato 5-Fosfatases , Doença de Parkinson/genética , Doença de Parkinson/metabolismo , Polimorfismo de Nucleotídeo Único/genética
3.
Comput Math Methods Med ; 2022: 4997393, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35509858

RESUMO

Objective: To analyze the role of C5a, C5a receptor (CD88), glutamic acid, and N-methyl-D-aspartic acid receptors (NMDAR1 and NMDAR2B) in the onset of neuromyelitis optica (NMO) disease in mice. Method: To select C57BL/6 wild-type (WT) mice and C5a receptor gene knockout (C5aR-/-) mice, use NMO-IgG and hemolytic complement to intervene in spinal cord tissue sections and optic nerves to establish an NMO model in vitro. The experiment was carried out with five groups (control group, WT group, C5aR-/- group, C5a group, and C5a+C5aRA group), with six mice in each group. The differences of American spinal cord injury (ASIA) motor scores were compared among all groups. The expressions of aquaporin (AQP4), glial fibrillary acidic protein (GFAP), NMDAR1, and NMDAR2B in spinal cord and optic nerve tissues were detected. The difference of glutamic acid (Glu) concentrations in culture solutions of the spinal cord and optic nerves was compared. Result: The ASIA motor score of the control group was significantly lower than that of the other four groups. The C5a-/- group was significantly higher than the WT group. The C5a+C5aRA group was significantly higher than the C5a group in terms of ASIA motor score. In the control group, AQP4 and GFAP showed expression loss. The C5aR-/- group's loss rate was significantly higher than that of the WT group. The loss rate of the C5a+C5aRA group was significantly higher than that of the C5a group. In the control group, the protein expressions of NMDAR1 and NMDAR2B were significantly lower than that of the other four groups. The C5aR-/- group was significantly higher than the WT group. The C5a+C5aRA group was significantly higher than the C5a group in protein expression. In the control group, the concentration of Glu in the C5aR-/- group was significantly higher than that in the WT group, and the C5a group was significantly lower than the C5a+C5aRA group. Conclusion: The deletion of the C5a receptor promotes NMDAR activity, which affects the toxic excitatory effect of NMDAR in NMO and regulates the neurotoxic effect of glutamic acid, thus participating in the pathogenesis of NMO.


Assuntos
Neuromielite Óptica , Traumatismos da Medula Espinal , Animais , Modelos Animais de Doenças , Ácido Glutâmico , Humanos , Camundongos , Camundongos Endogâmicos C57BL , N-Metilaspartato , Neuromielite Óptica/genética , Neuromielite Óptica/metabolismo , Receptor da Anafilatoxina C5a/genética
4.
Pak J Pharm Sci ; 34(3): 861-867, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-34602407

RESUMO

This experiment proposed to study the efficiency omega 3 fatty acid on behavioural phenotype of Parkinson's disease (PD) in mice. Totally 7 groups (each group 6 mice) were used in this assessment, each groups were treated with saline (control), MPP+, L-DOPA, Omega 3 oil, Omega 3 oil (three different concentrations) +MPP+ separately. The behavioral assessments such as bar test, open field test, maze test, hang test were noted on 7th, 14th, 21st and 28th day. After the examination period, the tested animals' midbrains and frontal cortex were dissected to analyze TBARS, GSH, Catalase, Superoxide Dismutase and Glutathione Peroxidase assay. In the bar test, 500mg omega 3 fatty acid administrated mice showed a high cataleptic scores. In open field Test, significant reductions in behavior analysis were observed from the tested mice group. Maze test and hang test doesn't show much difference. In biochemical test, tested groups showed promising results compared to control group. The result strongly proved that the omega 3 fatty acid has remarkable abilities to control the neurodegenerative diseases.


Assuntos
Antiparkinsonianos/farmacologia , Comportamento Animal/efeitos dos fármacos , Ácidos Graxos Ômega-3/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Transtornos Parkinsonianos/fisiopatologia , 1-Metil-4-fenilpiridínio/toxicidade , Animais , Catalase/efeitos dos fármacos , Catalase/metabolismo , Reação de Congelamento Cataléptica , Lobo Frontal/efeitos dos fármacos , Lobo Frontal/metabolismo , Glutationa/efeitos dos fármacos , Glutationa/metabolismo , Glutationa Peroxidase/efeitos dos fármacos , Glutationa Peroxidase/metabolismo , Levodopa/farmacologia , Masculino , Mesencéfalo/efeitos dos fármacos , Mesencéfalo/metabolismo , Camundongos , Teste de Campo Aberto , Transtornos Parkinsonianos/induzido quimicamente , Superóxido Dismutase/efeitos dos fármacos , Superóxido Dismutase/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
5.
Neurosci Lett ; 566: 247-51, 2014 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-24598438

RESUMO

OBJECTIVE: The restoration of blood flow to the brain after ischemic stroke prevents further, extensive damage but can result in reperfusion injury. The inflammation response is one of many factors involved in cerebral ischemia-reperfusion injury. This study investigated the use of vinpocetine, a drug used to treat cognitive impairment, to explore its effects on inflammation in a rat model of cerebral ischemia-reperfusion. METHODS: Wistar rats were randomly assigned to a control group, (n=40) a cerebral ischemia-reperfusion group (n=52) and a vinpocetine cerebral ischemia-reperfusion group (n=52). A model of middle cerebral artery occlusion was induced for 2h followed by reperfusion and the infarct size was determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining 6h, 24h, 3 days, and 7 days after reperfusion. The dry-wet weight method was used to measure brain water content and evaluate the extent of brain edema. Immunohistochemistry and in-situ hybridization were used to detect the expression of NF-κB and TNF-α. RESULTS: The NF-κB levels in ischemic brain tissue increased 6h after reperfusion and the TNF-α levels increased at 24h, both reached their peaks at day 3 then decreased gradually, but remained above the controls at day 7. Vinpocetine decreased the levels of NF-κB and TNF-α 24h and 3 days after reperfusion. CONCLUSION: NF-κB and TNF-α is associated with changes in brain edema and infarct volume. Vinpocetine decreases the expression of NF-κB and TNF-α and inhibits the inflammatory response after cerebral ischemia-reperfusion.


Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Isquemia Encefálica/metabolismo , NF-kappa B/metabolismo , Traumatismo por Reperfusão/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Alcaloides de Vinca/farmacologia , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Edema Encefálico/tratamento farmacológico , Edema Encefálico/patologia , Infarto Encefálico/tratamento farmacológico , Infarto Encefálico/metabolismo , Infarto Encefálico/patologia , Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/patologia , Masculino , RNA Mensageiro/metabolismo , Ratos Wistar , Traumatismo por Reperfusão/tratamento farmacológico , Traumatismo por Reperfusão/patologia , Fator de Necrose Tumoral alfa/genética , Alcaloides de Vinca/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA